Cytokines as mediators of depression: What can we learn from animal studies?

被引:339
|
作者
Dunn, AJ
Swiergiel, AH
de Beaurepaire, R
机构
[1] Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol, Shreveport, LA 71130 USA
[2] Polish Acad Sci, Inst Genet & Anim Breeding, Jastrzebiec, Poland
[3] Hop Paul Guiraud, Villejuif, France
[4] INSERM, Creteil, France
关键词
cytokines; depression; interleukins-1; interferon; norepinephrine; serotonin; HPA Axis; sickness behavior; animal models;
D O I
10.1016/j.neubiorev.2005.03.023
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
It has recently been postulated that cytokines may cause depressive illness in man. This hypothesis is based on the following observations: 1. Treatment of patients with cytokines can produce symptoms of depression; 2. Activation of the immune system is observed in many depressed patients; 3. Depression occurs more frequently in those with medical disorders associated with immune dysfunction; 4. Activation of the immune system, and administration of endotoxin (LPS) or interleukin-1 (IL-1) to animals induces sickness behavior, which resembles depression, and chronic treatment with antidepressants has been shown to inhibit sickness behavior induced by LPS; 5. Several cytokines can activate the hypothalamo-pituitary-adrenocortical axis (HPAA), which is commonly activated in depressed patients; 6. Some cytokines activates cerebral noradrenergic systems, also commonly observed in depressed patients; 7. Some cytokines activate brain serotonergic systems, which have been implicated in major depressive illness and its treatment. The evidence for each of these tenets is reviewed and evaluated along with the effects of cytokines in classical animal tests of depression. Although certain sickness behaviors resemble the symptoms of depression, they are not identical and each has distinct features. Thus the value of sickness behavior as an animal model of major depressive disorder is limited, so that care should be taken in extrapolating results from the model to the human disorder. Nevertheless, the model may provide insight into the etiology and the mechanisms underlying some symptoms of major depressive disorder. It is concluded that immune activation and cytokines may be involved in depressive symptoms in some patients. However, cytokines do not appear to be essential mediators of depressive illness. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:891 / 909
页数:19
相关论文
共 50 条
  • [41] Neurologic manifestations of COVID-19: what can we learn from other coronaviruses
    Jadali, Zohreh
    EGYPTIAN JOURNAL OF NEUROLOGY PSYCHIATRY AND NEUROSURGERY, 2020, 56 (01)
  • [42] Paying attention to relatives of cancer patients: What can we learn from their online writings?
    van Eenbergen, Mies C.
    van Engelen, Hanneke
    Ezendam, Nicole P. M.
    van de Poll-Franse, Lonneke, V
    Tates, Kiek
    Krahmer, Emiel J.
    PATIENT EDUCATION AND COUNSELING, 2019, 102 (03) : 404 - 410
  • [43] The impact of agricultural insurance on farmers' mental health: what we can learn from the literature
    Rana, Rezwanul Hasan
    Adeyinka, Adewuyi Ayodele
    Mushtaq, Shahbaz
    Barratt, Jonathan
    Alam, Khorshed
    ENVIRONMENT DEVELOPMENT AND SUSTAINABILITY, 2024,
  • [44] The role of cytokines as inflammatory mediators in osteoarthritis: Lessons from animal models
    Goldring, MB
    CONNECTIVE TISSUE RESEARCH, 1999, 40 (01) : 1 - 11
  • [45] What can we learn from trial decliners about improving recruitment? Qualitative study
    Hughes-Morley, Adwoa
    Young, Bridget
    Hempel, Roelie J.
    Russell, Ian T.
    Waheed, Waquas
    Bower, Peter
    TRIALS, 2016, 17
  • [46] Neurologic manifestations of COVID-19: what can we learn from other coronaviruses
    Zohreh Jadali
    The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 56
  • [47] Sex differences in how inflammation affects behavior: What we can learn from experimental inflammatory models in humans
    Lasselin, Julie
    Lekander, Mats
    Axelsson, John
    Karshikoff, Bianka
    FRONTIERS IN NEUROENDOCRINOLOGY, 2018, 50 : 91 - 106
  • [48] What we learn from arthritis models to benefit arthritis patients
    van den Berg, WB
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2000, 14 (04): : 599 - 616
  • [49] What can we learn from trial decliners about improving recruitment? Qualitative study
    Adwoa Hughes-Morley
    Bridget Young
    Roelie J. Hempel
    Ian T. Russell
    Waquas Waheed
    Peter Bower
    Trials, 17
  • [50] What Can We Learn From Chinese Randomized Controlled Trials? A Systematic Review and Meta-Analysis of Chinese Venlafaxine Studies
    Koesters, Markus
    Zhang, Ying
    Ma, Yong Chun
    Weinmann, Stefan
    Becker, Thomas
    Jin, Wei Dong
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2011, 31 (02) : 194 - 200